Core Viewpoint - The approval of PB-119 by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its product portfolio and commercial prospects [1] Group 1: Product Approval - The National Medical Products Administration of China has approved the new drug application for PB-119, a core product of the company [1] - PB-119 is a next-generation long-acting GLP-1 receptor agonist that requires weekly administration [1] - The product is recognized as a "major new drug creation" under a national science and technology major project, classifying it as a Category 1 original drug [1] Group 2: Strategic Partnerships - The company has entered into a strategic partnership with PDC FZ-LLC, a leading pharmaceutical research institution in the UAE [1] - This partnership grants PDC exclusive rights to develop, distribute, market, and commercialize the company's core product Visepegenatide (PB-119) in the Middle East and Africa [1] - The collaboration signifies a critical step in the company's global commercialization strategy [1] Group 3: Market Performance - The company's stock has seen an increase of over 5%, specifically a rise of 5.11%, reaching HKD 63.8, with a trading volume of HKD 29.2559 million [1]
派格生物医药-B涨超5% PB-119上市申请获批 公司加快全球商业化战略